Sebastian Stintzing

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Medicine, Oncology, Pharmacology +9

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

Sabine Tejpar, Sebastian Stintzing, Fortunato Ciardiello et al. · JAMA Oncology · 2016 · 722 citations · Full text

Medicine, Cancer Biology, Oncology +17

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 418 citations

Medicine, Oncology, Pharmacology +14

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann et al. · Annals of Oncology · 2016 · 344 citations · Full text

Medicine, Biostatistics, Oncology +17

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Sebastian Stintzing, Pratyaksha Wirapati, Heinz‐Josef Lenz et al. · Annals of Oncology · 2019 · 194 citations · Full text

Medicine, Oncology, Pharmacology +15